Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

EDP-305

Small molecule · developed by Enanta Pharmaceuticals

Phase 2 Most advanced trial (none active)
ENTA Developer
5 Registered trials

What is EDP-305?

EDP-305 is a drug studied in nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Gastroenterology
Developer
Enanta Pharmaceuticals, Inc (ENTA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
7716RH2FJT

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04378010 Phase 2 Non-Alcoholic Steatohepatitis Terminated ENTA
NCT03421431 Phase 2 Non-Alcoholic Steatohepatitis Completed ENTA
NCT03394924 Phase 2 Primary Biliary Cholangitis Completed ENTA
NCT03783897 Phase 1 NASH - Nonalcoholic Steatohepatitis Completed ENTA
NCT03207425 Phase 1 NASH Completed ENTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

NASHNASH - Nonalcoholic SteatohepatitisNon-Alcoholic SteatohepatitisPrimary Biliary Cholangitis

More from Enanta Pharmaceuticals

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the ENTA page.

Follow ENTA, the company behind EDP-305

See ENTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ENTA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.